Boston Scientific Corporation $BSX Shares Sold by Priebe Wealth Holdings LLC

Priebe Wealth Holdings LLC trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 25.1% in the second quarter, Holdings Channel reports. The fund owned 2,231 shares of the medical equipment provider’s stock after selling 749 shares during the period. Priebe Wealth Holdings LLC’s holdings in Boston Scientific were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares during the period. MRA Advisory Group acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $273,000. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after buying an additional 16,699 shares during the period. NS Partners Ltd lifted its holdings in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after buying an additional 5,704 shares during the period. Finally, New England Research & Management Inc. acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $1,133,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $95.41 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a fifty day moving average of $101.98 and a two-hundred day moving average of $101.87. The company has a market capitalization of $141.38 billion, a price-to-earnings ratio of 56.79, a PEG ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on BSX shares. Evercore ISI reduced their price target on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partners raised their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a report on Wednesday, October 1st. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.